The popularity of GLP-1 drugs has insurance companies scrambling to satisfy consumer access while reining in exorbitant costs.

Brian Evanko, Cigna's chief operating officer, noted that Cigna had increased stop-loss prices for 2025 because of the surge in claims.

Brian Evanko: Thank you, David. Before getting into our business performance, I'd like to share a few thoughts on the new roles that were announced in March for Ann and myself.

Brian Evanko, COO, noted that over 50% of Evernorth's employers provide coverage for weight management, while Cigna Healthcare's coverage is lower.

COO Brian Evanko explained the programs’ focus on affordability and clinical safety, noting 9 million members enrolled in EncircleRX.

Brian Evanko Good morning, Josh. I'll take the first part of the question and David will take the second.

Cigna (CI) unveils ENGUIDE, a specialized GLP-1 pharmacy to be launched next month as demand for obesity drugs like Wegovy soars. Read more here.

The new offering will be available next month, Chief Financial Officer Brian Evanko said on the insurer's earnings call on Friday. As part of EnReachRx, Evernorth will also launched EnGuide, a new ...

On Friday, the company’s health services unit Evernorth unveiled new programs in a reliable growth area: helping payers manage GLP-1 utilization. Cigna also posted first quarter results well ...

Cigna announced in March that it would replace Eric P. Palmer — the company’s executive vice president of enterprise strategy and CEO of Evernorth Health Services — with Brian Evanko, who is ...

Cigna Group has appointed Brian Evanko as president and COO of the company, effective March 31. Evanko has been serving as CEO of Cigna Healthcare since January 2024, with oversight of all Cigna ...

Cigna Group (NYSE:CI) has seen its share price increase by 11% over the last quarter amid various significant events within the company. Recently announced executive changes include Brian Evanko ...